Green Cross’s U.S. partner gets 'orphan drug' designation for novel anticancer drug

Green Cross Corp. said last Friday that JX-594 (pexastimogene devacirepvec), an investigational medicine its U.S. business partner Jennerex Biotherapeutics developed for patients suffering from hepatocellular carcinoma (HCC), has been designated as an orphan drug by the United States Food and Drug Administration (FDA).

The FDA provides orphan drug designation to drugs that seek to treat rare...